| AlloVax (CRCL/AlloStim) / Immunovative |
NCT02409524: An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects |
|
|
| Completed | 2a | 15 | RoW | AlloVax, CRCL and AlloStim, AlloStim, AlloStim ID, AlloStim IV, CRCL, Chaperone Rich Cell Lysate | Immunovative Therapies, Ltd. | Advanced Adult Hepatocellular Carcinoma | 06/17 | 03/19 | | |
NCT02624999: Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck |
|
|
| Withdrawn | 2 | 0 | RoW | AlloVax™, CRCL + AlloStim™, Cisplatin, Standard Chemotherapy | Immunovative Therapies, Ltd. | Squamous Cell Carcinoma Head and Neck | 12/16 | 05/17 | | |
NCT01998542: Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck |
|
|
| Completed | 2 | 12 | RoW | AlloVax, CRCL and AlloStim, CRCL, Chaperone Rich Cell Lysate, CRCL injection, AlloStim, AlloStim ID, AlloStim IV | Immunovative Therapies, Ltd. | Cancer of Head and Neck, Squamous Cell Carcinoma of the Head and Neck | 06/17 | 11/17 | | |
NCT01995227: An Individualized Anti-Cancer Vaccine Study in Patients With HCC |
|
|
| Withdrawn | 1/2 | 0 | RoW | AlloVax, AlloStim plus CRCL, CRCL, Chaperone Rich Cell Lysate, AlloStim, AlloStim ID, AlloStim IV | Immunovative Therapies, Ltd. | Hepatocellular Carcinoma | 02/18 | 07/18 | | |
